These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23444259)

  • 1. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
    Naeini KM; Pope WB; Cloughesy TF; Harris RJ; Lai A; Eskin A; Chowdhury R; Phillips HS; Nghiemphu PL; Behbahanian Y; Ellingson BM
    Neuro Oncol; 2013 May; 15(5):626-34. PubMed ID: 23444259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.
    Yang D; Rao G; Martinez J; Veeraraghavan A; Rao A
    Med Phys; 2015 Nov; 42(11):6725-35. PubMed ID: 26520762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.
    Zhang Z; Jiang H; Chen X; Bai J; Cui Y; Ren X; Chen X; Wang J; Zeng W; Lin S
    J Neurooncol; 2014 Aug; 119(1):207-14. PubMed ID: 24828264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
    Henker C; Kriesen T; Fürst K; Goody D; Glass Ä; Pützer BM; Piek J
    J Neurooncol; 2016 Feb; 126(3):585-92. PubMed ID: 26603163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
    Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
    Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma.
    Harris RJ; Cloughesy TF; Pope WB; Godinez S; Natsuaki Y; Nghiemphu PL; Meyer H; Paul D; Behbahanian Y; Lai A; Ellingson BM
    J Neurooncol; 2013 Apr; 112(2):257-66. PubMed ID: 23344788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
    Wang P; Shi YH; Li JY; Zhang CZ
    World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomic analysis of multi-contrast brain MRI for the prediction of survival in patients with glioblastoma multiforme.
    Chaddad A; Desrosiers C; Toews M
    Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():4035-4038. PubMed ID: 28325002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
    Stringfield O; Arrington JA; Johnston SK; Rognin NG; Peeri NC; Balagurunathan Y; Jackson PR; Clark-Swanson KR; Swanson KR; Egan KM; Gatenby RA; Raghunand N
    Tomography; 2019 Mar; 5(1):135-144. PubMed ID: 30854451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Mischel PS; Pope WB
    Neuro Oncol; 2011 Apr; 13(4):401-9. PubMed ID: 21324937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric assessment of glioblastoma and its predictive value for survival.
    Henker C; Hiepel MC; Kriesen T; Scherer M; Glass Ä; Herold-Mende C; Bendszus M; Langner S; Weber MA; Schneider B; Unterberg A; Piek J
    Acta Neurochir (Wien); 2019 Aug; 161(8):1723-1732. PubMed ID: 31254065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
    Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
    Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.